Wednesday, November 19, 2025 6:04:17 PM
Blue, I’m not ready at all to call this a failed investment. And even when it fell from 31 to 3 from 2021 to 2024.
I have suffered a few failed equities so I know how that is. This seems like a reset coming, not a rejection. A reorientation, restructuring, and maybe pushes the finish line out 2 more years. I can appreciate the sentiment of those like Doc, who might know better how that will work. As for anticipating the chart wave patterns coming, I think we just have to be patient and be prepared for fast falling knife type moves, that could easily dump down 70 or 80 cents at the open, and hit a 1 or 2 dollar target point, like the current price, sliding sideways now around 3.65/3.50 (3.40-3.70) I wouldn’t be surprised if it gets suddenly slammed down 1 dollar, or 70 cents , after lulling people to sleep this week moving sideways at 3.60 … I’m willing to buy some more for my portfolio at the historic bottom levels. (2.00-3.00 area) There should be chances next year to repair the price damage. Looking at the entire chart, of the last 13 years, AVXL has never floundered in the bottom zones like a dead fish. From every bottom, each time It made huge rally waves, as well as equally large downwaves from the top.
If this company is dead, then you would be right, I suppose.
But in any case everyone has to make their own decisions, and due diligence. I guess Sarepta showed us how important safety is. Anavex at least doesn’t have that problem .
I have suffered a few failed equities so I know how that is. This seems like a reset coming, not a rejection. A reorientation, restructuring, and maybe pushes the finish line out 2 more years. I can appreciate the sentiment of those like Doc, who might know better how that will work. As for anticipating the chart wave patterns coming, I think we just have to be patient and be prepared for fast falling knife type moves, that could easily dump down 70 or 80 cents at the open, and hit a 1 or 2 dollar target point, like the current price, sliding sideways now around 3.65/3.50 (3.40-3.70) I wouldn’t be surprised if it gets suddenly slammed down 1 dollar, or 70 cents , after lulling people to sleep this week moving sideways at 3.60 … I’m willing to buy some more for my portfolio at the historic bottom levels. (2.00-3.00 area) There should be chances next year to repair the price damage. Looking at the entire chart, of the last 13 years, AVXL has never floundered in the bottom zones like a dead fish. From every bottom, each time It made huge rally waves, as well as equally large downwaves from the top.
If this company is dead, then you would be right, I suppose.
But in any case everyone has to make their own decisions, and due diligence. I guess Sarepta showed us how important safety is. Anavex at least doesn’t have that problem .
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
